Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

Groupes Item: GENERAL INFORMATION, GENERAL INFORMATION, DISEASE, LYMPHOMA, TREATMENT GIVEN BEFORE THE 1ST TRANSPLANT, DISEASE HISTORY BEFORE HSCT, STATUS OF DISEASE AT HSCT, ADDITIONAL TREATMENT POST-HSCT, BEST DISEASE RESPONSE AT 100 DAYS POST-HSCT, FORMS TO BE FILLED IN, LYMPHOMA FOLLOW UP, GRAFT VERSUS HOST DISEASE (GvHD) SINCE LAST REPORT, OTHER COMPLICATIONS SINCE LAST REPORT, DATE(S) AND RESULTS OF ALL TESTS DONE FOR ALL DONORS, ADDITIONAL THERAPIES SINCE LAST FOLLOW UP, FIRST EVIDENCE OF RELAPSE OR PROGRESSION SINCE LAST HSCT, ADDITIONAL NOTES IF APPLICABLE

DOCUMENTED PATHOGENS (Use this table for guidance on the pathogens of interest) Bacteria: S. pneumoniae, Other gram positive (i.e.: other streptococci, staphylococci, listeria …), Haemophilus influenzae, Other gram negative (i.e.: E. coli klebsiella, proteus, serratia, pseudomonas …), Legionella sp, Mycobacteria sp, Other Fungi:Candida sp, Aspergillus sp, Pneumocystis carinii, Other Parasites: Toxoplasma gondii, Other Viruses: HSV, VZV, EBV, CMV, HHV-6, RSV, Other respiratory virus (influenza, parainfluenza,rhinovirus), Adenovirus, HBV, HCV, HIV, Papovavirus, Parvovirus, Other

EBMT Multiple Myeloma General Information - 16pp EBMT Multiple Myeloma 10PCD

- 29/06/2016 - 1 Formulaire, 18 Groupes Item, 283 Eléments de données, 1 Langue

Groupes Item: EBMT FORM GENERAL INFORMATION, PATIENT, DISEASE, PLASMA CELL DISORDERS (INCLUDING MULTIPLE MYELOMA), PRE-HSCT TREATMENT, HSCT, STATUS OF DISEASE AT COLLECTION, DISEASE STATUS AT HSCT, ADDITIONAL TREATMENT POST-HSCT, STATUS OF DISEASE AT 100 DAYS AFTER HSCT, FORMS TO BE FILLED IN, PLASMA CELL DISORDERS (INCLUDING MULTIPLE MYELOMA), PATIENT LAST SEEN, GRAFT VERSUS HOST DISEASE (GvHD) SINCE LAST REPORT, OTHER COMPLICATIONS SINCE LAST REPORT, ADDITIONAL THERAPIES SINCE LAST FOLLOW UP, FIRST EVIDENCE OF RELAPSE OR PROGRESSION SINCE LAST HSCT, LAST DISEASE AND PATIENT STATUS

DOCUMENTED PATHOGENS (Use this table for guidance on the pathogens of interest) Bacteria:S. pneumoniae,OHaemophilus influenzaether gram positive (i.e.: other streptococci, staphylococci, listeria …), Other gram negative (i.e.: E. coli klebsiella, proteus, serratia, pseudomonas …), Legionella sp,Mycobacteria sp, Other Fungi:Candida sp, Aspergillus sp, Pneumocystis carinii, Other Parasites: Toxoplasma gondii, Other Viruses: HSV, VZV, EBV,CMV,HHV-6, RSV,Other respiratory virus (influenza, parainfluenza, rhinovirus),Adenovirus, HBV, HCV, HIV,Papovavirus, Parvovirus, Other

dbGaP phs001282 Genomics of Endemic Burkitt Lymphoma - Eligibility

- 02/04/2023 - 5 Formulaires, 1 Groupe Item, 1 Élément de données, 1 Langue

Groupe Item: IG.elig

Principal Investigator: Ann M. Moormann, University of Massachusetts Medical School, Worcester, MA, USA MeSH: Burkitt Lymphoma,Lymphoma, Non-Hodgkin https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001282 This genomic landscape of Burkitt lymphoma represents a multimodal sequencing of tumors and control tissues and individuals to better understand the etiology, and molecular pathogenesis of Burkitt lymphoma including the roles of the associated Plasmodium falciparum malaria and EBV infections. Comprehensive sequencing set includes genomic, transcriptomic, and epigenomic datasets in concert with variable clinical phenotypes and outcome information such as anatomical presentation site, in-hospital survival rates, and EBV genome type. This deposit includes additional small RNA-seq data from endemic BL (eBL) tumors and RNA-sequencing data from sorted NK cell subsets from the peripheral blood of eBL patients. The additional small RNA-seq data are from tumor specimens from 17 eBL cases, of the previously deposited polyA RNA-seq data from 28 eBL cases (phs1282.V1). The additional RNAseq data from Fluorescence-activated cell sorting (FACS) of NK cell subsets, isolated from the peripheral blood of 7 eBL cases. *For initial transcriptome analysis see: Kaymaz et al.* "Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type-specific Difference." Molecular Cancer Research, 2017. PMID 28465297 *For initial microRNA analysis see: Oduor et al.* "Human and Epstein-Barr Virus miRNA Profiling as Predictive Biomarkers for Endemic Burkitt Lymphoma." Frontiers in Microbiology 8, 2017. PMID 28400759 *For initial NK subsets RNA expression analysis see: Forconi et al.* "A new hope for CD56negCD16pos NK cells as unconventional cytotoxic mediators: an adaptation to chronic diseases." Frontiers in Cellular and Infection Microbiology, Submitted and Under review. *For general overview of cohort study see: Buckle et al.* "Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study." Int J Cancer. 15:1231, 2016, PMID 27136063

pht006096.v2.p1

1 Groupe Item 3 Eléments de données

pht006098.v2.p1

1 Groupe Item 5 Eléments de données

pht006099.v2.p1

1 Groupe Item 12 Eléments de données

pht006097.v2.p1

1 Groupe Item 3 Eléments de données

Eligibility NCT00087646 Hepatitis C - Eligibility

- 11/12/2013 - 1 Formulaire, 3 Groupes Item, 20 Eléments de données, 2 Langues

Groupes Item: Inclusion criteria, Exclusion criteria, Medical Concepts

A Randomized, Open-label Study of the Effect of PEGASYS Combined With Ribavirin on Sustained Virologic Response in Patients With Chronic Hepatitis C Who Did Not Respond to Previous Pegintron/Ribavirin Combination Therapy Inclusion Criteria - adult patients >=18 years of age - CHC infection - liver biopsy (in <24 calendar months of first dose), with results consistent with CHC infection - use of 2 forms of contraception during study and 6 months after the study in both men and women - Lack of response to previous treatment with peginterferon alfa-2b (12KD)/ribavirin combination therapy given for >=12 weeks Exclusion Criteria - women who are pregnant or breastfeeding - male partners of women who are pregnant - conditions associated with decompensated liver disease - other forms of liver disease, including liver cancer - human immunodeficiency virus infection

EWOG MDS 2006 Infection DRKS00003789 - Infection

- 05/08/2014 - 1 Formulaire, 7 Groupes Item, 13 Eléments de données, 2 Langues

Groupes Item: Show identification of patient, Infection, Infection pathogen, Viral infection, CMV infection, EBV infection, Fungal infection

Prospective non–randomized multicenter study for epidemiology and characterization of Myelodysplastic Syndromes(MDS) and Juvenile Myelomonocytic Leukemia (JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer http://clinicaltrials.gov/ct2/show/NCT00662090 http://www.ewog-mds.org/

Top 300 Laboratory Value Dataset of the Medical Informatics Initiative Germany (MII) (Extended Version) - CHEM

- 06/12/2019 - 11 Formulaires, 139 Groupes Item, 447 Eléments de données, 1 Langue

Groupes Item: Creatinine, Potassium, Sodium, Glucose, C reactive protein, Alanine aminotransferase, Urea, Aspartate aminotransferase, Gamma glutamyl transferase, Albumin, Chloride, Glomerular filtration rate/1.73 sq M.predicted, Calcium.ionized, Calcium, Lactate dehydrogenase, Bilirubin, Creatine kinase, Alkaline phosphatase, Protein, Thyrotropin, Base excess, Urate, Lactate, Bicarbonate, Glomerular filtration rate/1.73 sq M.predicted, pH, Triacylglycerol lipase, Cholesterol.in LDL, C reactive protein, Phosphate, Thyroxine.free, Triiodothyronine.free, Triglyceride, Creatinine in Urine, Methemoglobin/Hemoglobin.total, Cholesterol, Acid phosphatase, Cholinesterase, pH in Urine, Cholesterol.in HDL, Ferritin, Troponin T.cardiac, Procalcitonin, Creatine kinase.MB, Natriuretic peptide.B prohormone N-Terminal, Iron, Calcidiol, Amylase, Beta 2 globulin/Protein.total, Beta 1 globulin/Protein.total, Albumin/Protein.total, Glutamate dehydrogenase, Alpha 1 globulin/Protein.total, Alpha 2 globulin/Protein.total, Beta globulin/Protein.total, Gamma globulin/Protein.total, Osmolality, Carcinoembryonic Ag, Cortisol, Albumin in Urine, Cystatin C, Cobalamins, IgM, IgG, Troponin I.cardiac, Folate, Transferrin, Lutropin, Myoglobin, IgA, Prostate specific Ag, Cholesterol.in LDL/Cholesterol.in HDL, Parathyrin.intact, Interleukin 6, Estradiol, Follitropin, Lipoprotein (little a), Bilirubin.glucuronidated+Bilirubin.albumin bound, Natriuretic peptide.B, Interpretation, Beta-2-Microglobulin, Alpha-1-Microglobulin in Urine, Angiotensin converting enzyme, Immunoglobulin light chains.kappa.free, Base excess^^standard, Protein/Creatinine in Urine, Testosterone, S100 calcium binding protein B, IgE, Prolactin, Bicarbonate^^standard, Osmolality in Urine, Cancer Ag 19-9, IgG in Urine, Osteocalcin, Protein, Ammonia, Bilirubin.non-glucuronidated, Lactate, Creatinine renal clearance, Homocysteine, Pyridoxal phosphate, Glucose, Calcium in Urine, Phosphate in Urine, Choriogonadotropin.beta subunit, Iron saturation, Sodium in Urine, Tumor necrosis factor.alpha, Protein, Corticotropin, Interleukin 2 receptor, Thyroglobulin, Progesterone, Alpha-2-Macroglobulin/Protein.total, Albumin/Creatinine in Urine, Lactate dehydrogenase, Enolase.neuron specific, Thiamine, Insulin-like growth factor-I, Immunoglobulin light chains.lambda.free, Dehydroepiandrosterone sulfate, Creatinine, Albumin, IgG, Bilirubin.glucuronidated, Choriogonadotropin (pregnancy test) in Urine, Holo-transcobalamin II, IgA, Albumin, IgM, Testosterone.free, Prostate specific Ag.free, Aldosterone, Triacylglycerol lipase, Sex hormone binding globulin, Urea in Urine, IgG subclass 4, Creatine kinase.MB/Creatine kinase.total

The Top 300 Dataset (Kerndatensatz Labor) was developed by the Medical Informatics Initiative Germany (MII) and contains frequency-sorted, LOINC-coded analyses of the university clinics in Göttingen, Gießen, Munich, Greifswald and Erlangen. This form shows a detailed description containing primary and secondary LOINC codes of the 300 most common laboratory parameters. For each of the 300 laboratory parameters an itemgroup was created with all accepted variants of the laboratory parameters as items (secondary LOINC codes), the first item being the preferred LOINC variant of the MII (primary LOINC code). The itemgroup title is based on the primary LOINC code. The list is divided into subforms by the associated classes of laboratory parameters. If more than one class, the parameters can be found in the MIXED subform. An overview of the preferred presentation can also be found in the MDM portal (Laboratory Tests (Overview)). https://www.medizininformatik-initiative.de/de/labordaten-in-der-medizininformatik-initiative Explanation of abbreviations for types of specimen and classes/subforms: Type of specimen: Bld = Blood BldA = arterial blood Ser = Serum Plas = Plasma RBC = Red blood cells PPP = Platelet poor plasma Urine sed = Urine sediment CSF = Cerebral spinal fluid Body fld = Body fluid Classes (Subforms): CHEM = Chemistry HEM/BC = Hematology/Blood Cell Count COAG = Coagulation study UA = Urinalysis CELLMARK = Cell markers CLIN = clinical not elsewhere classified DRUG/TOX = drug levels & toxicology SERO = serology MICRO = Microbiology SPEC = Specimen characteristics

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Oncological sub-cohort

- 16/07/2021 - 23 Formulaires, 10 Groupes Item, 47 Eléments de données, 1 Langue

Groupes Item: Underlying disease: Hematological diseases, Solid tumors, Other underlying diseases, NHL, Time of first diagnosis, BL (Oncological status), Prior anti-cancer therapy, Stem cell transplantation, Hypogammaglobuliaemia, Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. Please note that only cases with known outcome are collected! Baseline / diagnosis is defined as the day the sample of the first positive SARS-CoV-2 result was taken. Criteria of the Uncomplicated Phase: Asymptomatic OR Symptoms of upper respiratory tract infection and/or Nausea, emesis, diarrhea and/or Fever Remember: The Uncomplicated Phase ends, if a previously febrile patient has no fever anymore and has completed 14 days of follow-up without entering Complicated or Critical Phase; then move to Recovery Phase. Also, as soon as one of the criteria of the Complicated or Critical Phase are fulfilled, Uncomplicated Phase ends; move over to there. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Complicated Phase: * Need for oxygen supplementation (In patients with prior oxygen home therapy, clinically meaningful increase in need for oxygenation.) * paO2 at room air < 70 mmHg * SO2 at room air < 90 % * GOT or GPT > 5x ULN * New cardiac arrhythmia * New pericardial effusion >1cm * New heart failure with pulmonary edema, congestive hepatopathy or peripheral edema Remember: The Complicated Phase ends, if none of the criteria for the Complicated Phase is fulfilled anymore AND the patient is free of fever; then move to Recovery Phase. Also, as soon as one of the criteria of the Critical Phase are fulfilled, Complicated Phase ends; move over to Critical Phase. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Critical Phase: * Need for catecholamines * Life-threatening cardiac arrhythmia * Mechanical ventilation (invasive or non-invasive) * Liver failure with Quick< 50% * qSOFA >= 2 * Renal failure in need of dialysis Remember: The Critical Phase ends as soon as none of the criteria for the Critical Phase is fulfilled anymore AND the patient is free of fever. If the patient has died, it ends with the death of the patient. If the patient has died, do not report terminal values, i.e. those recorded after turning off life-support or heart rate "0" after death of the patient. Criteria of the Recovery Phase: *Improvement by at least one phase, i.e. Critical to Complicated or Complicated to Uncomplicated * Defervescence Remember: Uncomplicated asymptomatic patients enter recovery phase after 14 days of observation without disease progression No further progression or re-hospitalization If a text field can't be filled out, note 'ND' (for not determined).

Mots-clés

Table des matières

Modèles de données sélectionnés

dbGaP phs000260 Foregut Microbiome in Development of Esophageal Adenocarcinoma - pht001256.v4.p2

Eligibility

pht001257.v4.p2

pht001258.v4.p2

pht001259.v4.p2

Eligibility Bloodstream Infection in Cancer Patient DRKS00003368 NCT01544686 DRKS00003368 - Eligibility Bloodstream Infection in Cancer Patient NCT01544686 DRKS00003368

dbGaP phs001381 Gut Microbiome and Types of Colorectal Polyps - Eligibility

pht006566.v1.p1

pht006568.v1.p1

pht006567.v1.p1

pht006569.v1.p1

Eligibility Ductal Breast Carcinoma In Situ NCT02370277

Infection Episode

General Info EBMT Lymphoma - 16pp General Info EBMT Lymphoma 04 Lym.